nejm semaglutide heart failure New in the August 14, 2025, issue of NEJM: ⁣ ⁣ Cagrilintide–Semaglutide for Overweight or Obesity (REDEFINE 1 phase 3a trial)⁣ ⁣ Cagrilintide– for Overweight and Diabetes (REDEFINE 2 phase 3a trial)⁣ ⁣ STEP-HFpEF Trial

HEK293 cells were transiently transfected with GLP-1 receptor and cyclic-AMP sensor using YFP-Epac-RLuc (CAMYEL)

maximum 8 doses/month recommended Instructions : Gently shake the bottle, prime before first use, and avoid blowing nose immediately after administration Dosing can be adjusted based on individual response and tolerability

Horne JA, stberg O

M.Yockell-LelievreJ.GruslinA.AdamoK

And we adjust as needed

Abstract Many local and systemic diseases especially diseases that are leading causes of death globally like chronic obstructive pulmonary disease, atherosclerosis with ischemic heart disease and stroke, cancer and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing coronavirus disease 19 (COVID-19), involve both, (1) oxidative stress with excessive production of reactive oxygen species (ROS) that lower glutathione (GSH) levels, and (2) inflammation